key: cord-0831407-mwm8z2pm
authors: Rapaka, Rekha R; Hammershaimb, Elizabeth A; Neuzil, Kathleen M
title: Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines
date: 2021-03-06
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab213
sha: 82800438b8799cf5cdeb9c87f089e1b1ad682d7e
doc_id: 831407
cord_uid: mwm8z2pm

COVID-19 vaccine trials provide valuable insight into the safety and efficacy of vaccines, with individually-randomized, placebo-controlled trials being the gold standard in trial design. However, a myriad of variables must be considered as clinical trial data are interpreted and used to guide policy decisions. These variables include factors such as the characteristics of the study population and circulating SARS-CoV-2 strains, the force of infection, the definition and ascertainment of endpoints, the timing of vaccine efficacy assessment, and the potential for performance bias. In this Viewpoint, we discuss critical variables to consider when comparing efficacy measurements across current and future COVID-19 vaccine trials.

A c c e p t e d M a n u s c r i p t potential differences in studies such as characteristics of the study population and circulating SARS-CoV-2 strains, force of infection, definition and discovery of endpoints, the precise window of vaccine efficacy measurement, and factors impacting performance bias. These parameters may not be fully available in press releases or early release publications (see Table 2 ) and some of these features, such as virus strain features, may be unknown even after the trial is published. Simple comparisons of point estimates of efficacy without contextualization could lead to incomplete or inaccurate conclusions on the value of COVID-19 vaccines and could undermine confidence in the products. Herein, we summarize critical variables to consider when evaluating vaccine trial outcomes.

The choice of experimental population in any given clinical trial is based on several factors, including generalizability to the population in whom the intervention will be used, feasibility of follow-up to ensure uniform and high rates of study outcome ascertainment, and clinical equipoise. Differences in the presence of medical comorbidities and other social determinants of health may also affect overall efficacy results. Some trials may exclude participants with pre-existing conditions that could impact their response to either infection or vaccine, while another trial might include such participants. For example, Novavax reported a modest decline in vaccine efficacy against symptomatic disease in South Africa when HIVinfected individuals were included in the analysis [11] . Similarly, some trials enrolled fewer elderly participants, a population in which both immunosenescence and increased susceptibility to COVID-19 and severe disease must be considered. The original phase 3 ChAdOx1 nCOV19 trial, for example, demonstrated higher vaccine efficacy in study participants who received a half-dose in their initial immunization, but this cohort consisted of individuals only ages 18-55 years [5] . In the U.S., African American, LatinX, and Native

American individuals have increased rates of COVID-19 and of severe disease in particular, which may be related to social determinants of health [13] . The variable inclusion of racial A c c e p t e d M a n u s c r i p t and ethnic minorities across trials may, consequently, affect estimates of vaccine efficacy as a function of increased force of infection in these communities.

As more COVID-19 vaccines are approved, those at highest risk for becoming infected or for acquiring severe COVID-19 disease will have access to a vaccine through national allocation and distribution. The mRNA vaccine efficacy studies conducted by Pfizer-BioNTech and NIAID-Moderna occurred at a time when no vaccines against COVID-19 were available, and they enrolled relatively high percentages of participants 65 years of age and over [3, 4] . Emergency Use Authorizations issued in December 2020 and the current rollout of vaccines to priority populations of the U.S. will change the population available for ongoing and future vaccine efficacy trials. Randomization is intended to assure comparability of groups within trials but not between trials. While subgroup analyses, such as efficacy by age, may partly standardize comparisons, these cannot overcome the unmeasured differences in populations between trials.

Baseline seropositivity for SARS-CoV-2 antibodies, consistent with prior exposure to SARS-CoV-2, will increase over time and may impact vaccine efficacy estimates.

Individuals with preexisting anti-spike glycoprotein IgG are at significantly reduced risk of developing PCR-confirmed infection over a period of at least 6 months [14] . Beyond decreased baseline risk for SARS-CoV-2 reinfection, evidence has emerged demonstrating that seropositive participants have enhanced immune responses after a single dose of vaccine when compared to seronegative recipients [15] . The mRNA vaccine trials and the ChAdOx1 nCOV19 trial excluded participants in their primary analysis who were either seropositive at baseline or without baseline serologic results. Assessing vaccine efficacy in seropositive individuals after vaccination or infection will likely be factored into future trials, given the importance of this question clinically and increasing seropositivity rates globally.

A c c e p t e d M a n u s c r i p t SARS-CoV-2 strains, prevalence, and transmission dynamics Characteristics of the SARS-CoV-2 strains and evolving variants and the intensity of circulation will differ between COVID-19 vaccine clinical trials. The B.1.1.7 variant, first identified in the U.K. [16, 17] , is associated with increased transmission, potentially increased virulence [18, 19] , and is now the dominant variant in the U.K. and spreading quickly throughout the U.S. The B.1.351 variant, with more consequential changes to the spike glycoprotein than B.1.1.7, and also associated with increased transmissibility, was first identified in South Africa in October 2020 [20] and observed in the U.S. by the end of variant when compared to the strain used to generate the vaccine [23, 24] . As the pandemic continues, new strains with mutations in the spike glycoprotein will emerge.

Characterization of strain diversity as it affects transmission, virulence, and response to the vaccine will be a critical factor in the accumulation of endpoints and in determination of vaccine efficacy both within and between trials.

In addition to the viral strain, other factors affect transmission dynamics during a single trial or between trials. The intensity of the epidemic, for example, may have A c c e p t e d M a n u s c r i p t contributed to the differences in efficacy estimates between countries. The number of infectious challenges to the host, and a higher inoculum of virus per challenge, may be present in settings where population density is greater and/or the epidemic is more intense.

Large multicenter trials can control for some of these effects by enrolling participants at geographically diverse sites with varying transmission rates. Comparing attack rates in the placebo groups of different trials is one way to assess intensity of transmission during study conduct, and will be an important factor to compare, for example, when the Novavax data from the U.K. and South Africa are available in the peer-reviewed literature.

Nonpharmaceutical interventions aimed at reducing the force of infection, such as masking and restrictions on movement, may also impact trial endpoints. In the context of COVID-19, the imposition of mitigation measures has been associated with a decrease in transmission, while lifting of those restrictions is associated with increases in transmission [25] . The use of masks may reduce the viral inoculum to which the wearer is exposed, allowing wearers to mount an immune response to SARS-CoV-2 without causing clinicallysignificant disease [26] . As such, the effect of the vaccine in preventing COVID-19 may be difficult to differentiate from the effects of mitigation measures or naturally-derived immunity.

None of the efficacy trials to date have consistently evaluated the application of nonpharmaceutical interventions across study sites nor personal adherence to those measures amongst study participants, although all participants were encouraged to use appropriate infection control measures.

Case ascertainment and endpoint definitions COVID-19 infections differ widely in their clinical manifestations with subsets characterized by asymptomatic/presymptomatic, mild, moderate, severe, and critical categories. The published phase 3 studies have focused on the assessment of any symptomatic SARS-CoV-2 infection as a primary outcome; however, definitions differ between trials [27] . Likewise, criteria for sample collection differ between trials. Testing on A c c e p t e d M a n u s c r i p t the basis of milder symptoms will identify more cases, in contrast testing only those with more severe symptoms will reduce the number evaluated.

The case definitions and case ascertainment criteria are particularly relevant if vaccine efficacy estimates differ by vaccine severity, as indicated in early results from the adenoviral vector constructs [5, 12] . Prevention of severe disease is an important measure of public health impact for any COVID-19 vaccine and is the ultimate goal of most vaccination programs. While efficacy results have varied considerably for any symptomatic disease across trials, the efficacy results against severe disease have been more consistently robust. For the Oxford ChAdOx1 nCOV19 vaccine, efficacy of two doses of the vaccine was demonstrated at the interim analysis of 131 cases, which pooled data from Brazil and the U.K., to be 70.4% against symptomatic COVID-19 [5] , which is lower than the mRNA point estimates. For the severity endpoint, from 21 days after the first dose, there were ten cases hospitalized for COVID-19, all in the control arm; two of the ten were classified as severe COVID-19 according to the World Health Organization's 10-point clinical progression scale [28] , including one death [5] . While the Oxford ChAdOx1 nCOV19 cohort referred above was smaller, and hence the vaccine efficacy measurement is associated with wider confidence intervals, the vaccine efficacy approaches 100% in prevention of severe disease.

An additional example of increasing efficacy by increasing level of severity can be inferred by the limited results available in a press release for the single dose Janssen Ad26COV2S trial conducted in the U.S. and seven other countries. Overall, the level of protection for the combined endpoint of moderate-to-severe disease was 66%, with variation from 57% in South Africa to 72% in the United States [10, 12] . Importantly, the efficacy against severe disease, defined as laboratory-confirmed SARS-CoV-2 plus evidence of severe systemic illness, respiratory failure, shock, significant organ dysfunction, hospital intensive care unit admission or death, was 85% across geographies. Five COVID-19related deaths were reported in the placebo group, and none in the vaccine group. Having the data presented in a peer-reviewed journal will aid in fully interpreting the results [12] . 

In the U.S. and other developed countries, increasing availability and use of therapies such as corticosteroids and remdesivir in hospitalized patients and of monoclonal antibodies in non-hospitalized patients may confound interpretation of vaccine trial endpoints such as severe disease and death as these therapies reduce mortality [30] , time to recovery and hospital discharge [31, 32] , and rates of hospitalization [33] . Standards of care and available preventative medications and therapeutics may differ widely depending on region.

As the standard of care for the treatment of COVID-19 changes to reflect emerging data about therapeutic interventions in inpatient and outpatient settings, future trials are likely to skew toward less severe disease, and comparison of efficacy data across vaccine trials should consider this difference.

The ultimate success of vaccination programs is measured by the ability to prevent disease, not the ability to achieve a high point estimate of efficacy in an individuallyrandomized clinical trial. For example, the highly efficacious two-dose mRNA vaccines require stringent cold chain distribution and storage conditions, a minimum number of doses per shipment, and availability of medical management for anaphylaxis [34] . Therefore, an mRNA vaccine program is not feasible in many settings. Vaccines that are moderately efficacious against disease, and able to reach large segments of the population because of greater supply, single dose formulations, improved delivery characteristics, or greater acceptability will yield substantial public health gains (Table 1) .

A c c e p t e d M a n u s c r i p t

In the past year, the world has suffered extreme clinical, social and financial consequences of the COVID-19 pandemic. The vaccine development response to this critical need has been historic in terms of speed, product diversity, and robustness of clinical and regulatory evaluation. Thus far, efficacy estimates against symptomatic illness for both mRNA vaccines tested in the U.S. have far exceeded the FDA minimum criteria of 50%.

While these high point estimates of efficacy are impressive, the most important measures of vaccine impact from the public health standpoint are number of cases, and severe cases, prevented. Peer-reviewed data from U.S. studies of non-mRNA vaccines are pending, although data available from other countries or through press release strongly suggest that spike glycoprotein based constructs will markedly reduce severe disease outcomes.

Variant strains have been recognized since early in the pandemic and emerged before introduction of vaccines. The cross-protective effects of vaccination as measured by early immunogenicity and disease outcomes are reassuring, albeit imperfect [11, 23] . How 

K.N. reports grants from NIH to participate in overall organization of COVID vaccine trials and participation in vaccine trials. K.N. also reports grants from Pfizer to conduct clinical trials on COVID vaccines. K.N. receives no salary support on this grant. E.H. reports personal fees from the University of Oxford, outside the submitted work. E.H. serves as a coinvestigator for the phase 3 COVID-19 vaccine trials sponsored by Novavax and Moderna but received no financial support for these activities. E.H. also serves on the Endpoint Adjudication Committee for the phase 3 COVID-19 vaccine trial sponsored by Oxford-AstraZeneca and receives an hourly fee. R.R. is a co-investigator on COVID-19 vaccine trials sponsored by NIAID-Moderna, Pfizer, and Novavax and has volunteered as an endpoint assessor for the Oxford-AstraZeneca vaccine trial. M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t Certain populations may be more likely to develop severe disease. If efficacy varies by severity, this could contribute to efficacy differences between trials.

Novavax trial, inclusion of HIV-infected individuals in analysis led to slightly lower efficacy estimates [11] Virus characteristics The efficacy of vaccine may be diminished if the predominant virus strain does not match the vaccine strain.

Janssen ENSEMBLE trial, relatively lower vaccine efficacy noted in S. Africa, where 94.5% of vaccinees were infected with the B.1.351 lineage, while efficacy of 72% was observed in the U.S. [10] Force of infection Higher force of infection may overwhelm vaccine induced immunity and decrease efficacy estimates.

Attack rates are higher in the placebo group in Janssen ENSEMBLE trial compared to the placebo group in the Pfizer-BioNTech trial in the primary interim analysis [3, 10] Definition and ascertainment of endpoint If efficacy varies by severity, this could contribute to efficacy differences between trials.

Even comparing similar endpoints (e.g. severe disease) between trials will be biased by varying definitions of severity.

NIAID-Moderna trial criteria for severe COVID-19 could be characterized by features of SpO2 ≤93% on room air [4] , see protocol for detail; while the ChAdOx1 nCoV-19 trial defined severe COVID-19 by a WHO clinical progression scale score of 6 or greater, requiring at minimum respiratory support of high-flow oxygen or non-invasive positive pressure ventilation [5] .

Timing of vaccine efficacy assessment

Longer period of follow-up assesses a more durable immune response and a longer period of vaccine efficacy Effect of vaccine may be diluted by counting cases early on, prior to development of an effective adaptive immune response Pfizer trial, efficacy 52.4% against any protocol-defined COVID-19 disease between 1 st and 2 nd dose; estimate increases to 94.8% if cases are counted between day 15 and 21 [29] Performance bias: Availability of treatments Differential use of prophylactic or therapeutic treatments will affect number of severe cases and outcome of cases and could affect efficacy estimates This data has not been reported with trial results thus far

World Health Organization

A strategic approach to COVID-19 vaccine R&D

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

gov (NCT04611802)

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Vaccine for the Prevention of COVID-19

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Available at

Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

B.1.1.7 report. Global Report Investigating Novel Coronavirus Haplotypes

Increased infections, but not viral burden, with a new SARS-CoV-2 variant

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries

Facial Masking for Covid-19 -Potential for "Variolation" as We Await a Vaccine

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Remdesivir for the Treatment of Covid-19 -Final Report

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

Pfizer and BioNTech submit COVID-19 vaccine stability data at standard freezer temperature to the U

Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Available at

COVID-19: Developing Drugs and Biological Products for Treatment or Prevention Guidance for Industry

A c c e p t e d M a n u s c r i p t